EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The next “sweet” spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection

Yuanwei Xu, Yuefan Wang, Naseruddin Höti, David J Clark, Shao-Yung Chen, Hui Zhang

Mass Spectrometry Reviews · 2023-03 · 42 (2) · 822-843

DOI: 10.1002/mas.21748 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Mass Spectrometry Reviews, online erschienen am 12.11.2021. Verfasst von Yuanwei Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 235 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is the most common neoplastic disease of the pancreas, accounting for more than 90% of all pancreatic malignancies. As a highly lethal malignancy, PDAC is the fourth leading cause of cancer‐related deaths worldwide with a 5‐year overall survival of less than 8%. The efficacy and outcome of PDAC treatment largely depend on the stage of disease at the time of diagnosis. Surgical resection followed by adjuvant chemotherapy remains the only possibly curative therapy, yet 80%–90% of PDAC patients present with nonresectable PDAC stages at the time of clinical presentation. Despite our advancing knowledge of PDAC, the prognosis remains strikingly poor, which is primarily due to the difficulty of diagnosing PDAC at the early stages. Recent advances in glycoproteomics and glycomics based on mass spectrometry have shown that aberrations in protein glycosylation plays a critical role in carcinogenesis, tumor progression, metastasis, chemoresistance, and immuno‐response of PDAC and other types of cancers. A growing interest has thus been placed upon protein glycosylation as a potential early detection biomarker for PDAC. We herein take stock of the advancements in the early detection of PDAC that were carried out with mass spectrometry, with special focus on protein glycosylation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansPancreasPrognosisGlycoproteinsBiomarkers, Tumor

Substanzen

GlycoproteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Xu, Y., Wang, Y., Höti, N., Clark, D. J., Chen, S. Y., & Zhang, H. (2023). The next “sweet” spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection. Mass Spectrometry Reviews, 42(2), 822-843. https://doi.org/10.1002/mas.21748

Vancouver

Xu Y, Wang Y, Höti N, Clark DJ, Chen SY, Zhang H. The next “sweet” spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection. Mass Spectrometry Reviews. 2023;42(2):822-843. doi:10.1002/mas.21748

BibTeX
@article{Xu2023,
  author = {Xu, Yuanwei and Wang, Yuefan and Höti, Naseruddin and Clark, David J and Chen, Shao-Yung and Zhang, Hui},
  title = {The next “sweet” spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection},
  journal = {Mass Spectrometry Reviews},
  year = {2023},
  volume = {42},
  number = {2},
  pages = {822--843},
  doi = {10.1002/mas.21748}
}
Kostenlos starten →